ArticleEuropean journal of heart failure2019

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

John J V McMurray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.